The current study was designed to identify and characterize NPR2 loss-of-function mutations in patients with AMDM and to explore therapeutic responses to recombinant growth hormone (rhGH). This evidence concerns the gene GH1 and acromesomelic dysplasia 1, Maroteaux type.